Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-Intron
Status:
Terminated
Trial end date:
2018-02-09
Target enrollment:
Participant gender:
Summary
This is an open-label, single-arm, multicenter Phase II safety and efficacy study of
combination therapy with pembrolizumab and Sylatron (Peginterferon alpha-2b) in patients with
advanced cholangiocarcinoma who have progressed on or cannot tolerate frontline chemotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
Aiwu Ruth He, MD Georgetown University
Collaborators:
Duke University Georgetown University Hoosier Cancer Research Network Merck Sharp & Dohme Corp. Roswell Park Cancer Institute The Cleveland Clinic